Cheap copycat puts new pressure on plan costs, regulators, and big pharma margins Hims & Hers just put a US$49 GLP1 pill on the table, and that matters a lot more for drug pricing than for telehealth hype, according to Reuters
In the consumer staples sector, Anheuser Busch InBev and The Hershey Company have seen their stocks decline as investors start to ponder what demand could look like for their various products over the long term as these companies market products that are generally unhealthy for consumption
As a professional, I also assess: Blood sugar levels Blood pressure patterns Cravings and appetite irregularities Energy levels Sleep quality Family history Many patients with the same BMI have very different metabolic needs
This level of investment from a major pharmaceutical company like Eli Lilly signals strong confidence in the compounds long-term viability
Ozempic Ozempic is typically prescribed for the management of type 2 diabetes
The deficit is established and sustainable
